Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1964 2
1974 2
1975 7
1976 6
1977 10
1978 4
1979 9
1980 12
1981 20
1982 11
1983 15
1984 24
1985 24
1986 19
1987 33
1988 42
1989 48
1990 47
1991 44
1992 39
1993 37
1994 52
1995 70
1996 64
1997 61
1998 69
1999 87
2000 89
2001 84
2002 83
2003 66
2004 78
2005 93
2006 107
2007 105
2008 121
2009 139
2010 154
2011 188
2012 223
2013 209
2014 242
2015 255
2016 173
2017 129
2018 166
2019 183
2020 215
2021 249
2022 229
2023 162
2024 34

Text availability

Article attribute

Article type

Publication date

Search Results

4,170 results

Results by year

Filters applied: . Clear all
Page 1
PARP inhibitors: Synthetic lethality in the clinic.
Lord CJ, Ashworth A. Lord CJ, et al. Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16. Science. 2017. PMID: 28302823 Free PMC article. Review.
The DNA damage response and cancer therapy.
Lord CJ, Ashworth A. Lord CJ, et al. Nature. 2012 Jan 18;481(7381):287-94. doi: 10.1038/nature10760. Nature. 2012. PMID: 22258607 Review.
CD4 T Cells in IBD: Crossing the Line?
Boden EK, Lord JD. Boden EK, et al. Dig Dis Sci. 2017 Sep;62(9):2208-2210. doi: 10.1007/s10620-017-4655-2. Epub 2017 Jun 23. Dig Dis Sci. 2017. PMID: 28646283 No abstract available.
Transcription factor-driven regulation of ILC1 and ILC3.
Schroeder JH, Howard JK, Lord GM. Schroeder JH, et al. Trends Immunol. 2022 Jul;43(7):564-579. doi: 10.1016/j.it.2022.04.009. Epub 2022 May 23. Trends Immunol. 2022. PMID: 35618586 Free PMC article. Review.
Early reports highlighted group 1 and 3 ILC regulatory transcription factors (TFs), T-box expressed in T cells (T-bet; Tbx21) and RAR-related orphan nuclear receptor gammat (RORgammat; Rorc), as key regulators of ILC biology. ...
Early reports highlighted group 1 and 3 ILC regulatory transcription factors (TFs), T-box expressed in T cells (T-bet; …
Themed issue: Inflammation, repair and ageing.
Mauro C, Naylor AJ, Lord JM. Mauro C, et al. Br J Pharmacol. 2022 May;179(9):1787-1789. doi: 10.1111/bph.15799. Epub 2022 Feb 17. Br J Pharmacol. 2022. PMID: 35174874 Free PMC article. No abstract available.
Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
Schmitz RSJM, Engelhardt EG, Gerritsma MA, Sondermeijer CMT, Verschuur E, Houtzager J, Griffioen R, Retèl V, Bijker N, Mann RM, van Duijnhoven F, Wesseling J, Bleiker EMA; Grand Challenge PRECISION Consortium. Schmitz RSJM, et al. Eur J Cancer. 2023 Oct;192:113276. doi: 10.1016/j.ejca.2023.113276. Epub 2023 Aug 4. Eur J Cancer. 2023. PMID: 37657228 Free PMC article.
This implies overtreatment of indolent DCIS. The non-randomised patient preference LORD-trial tests whether active surveillance (AS) for low-risk DCIS is safe, by giving women with low-risk DCIS a choice between AS and conventional treatment (CT). ...Women opting for AS mo …
This implies overtreatment of indolent DCIS. The non-randomised patient preference LORD-trial tests whether active surveillance (AS) …
Autism spectrum disorders.
Lord C, Cook EH, Leventhal BL, Amaral DG. Lord C, et al. Neuron. 2000 Nov;28(2):355-63. doi: 10.1016/s0896-6273(00)00115-x. Neuron. 2000. PMID: 11144346 Free article. Review. No abstract available.
4,170 results